# DIAMOND

Source: https://onco.cc/trials/diamond/  
OnCo record `diamond` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DIAMOND, a UK trial run from Barts in London, asks whether adding the immunotherapy durvalumab to the antibody-drug conjugate datopotamab deruxtecan helps women with PD-L1-negative metastatic triple-negative breast cancer, the group immunotherapy alone does not help. It opened in October 2025 and is recruiting 140 patients.

## Summary

DIAMOND (NCT06954480; also on the ISRCTN registry) is an open-label randomised phase 2 trial sponsored by Queen Mary University of London with AstraZeneca, randomising 140 patients with PD-L1-negative metastatic triple-negative breast cancer to datopotamab deruxtecan with durvalumab or datopotamab deruxtecan alone; the primary endpoint is progression-free survival by RECIST 1.1. It started on 27 October 2025 with primary completion expected in February 2028. Its rationale is the BEGONIA arm 7 result (confirmed response 79 percent with the combination regardless of PD-L1) against the TROPION-Breast02 result for the conjugate alone in a 90 percent PD-L1-negative population, and it is the only randomised test of an ADC plus checkpoint inhibitor restricted to PD-L1-negative disease. Sites: Barts Cancer Institute Centre of Experimental Cancer Medicine and Barts Health NHS Trust, London.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Registry id: NCT06954480
- Phase: 2
- Setting: PD-L1-negative metastatic triple-negative breast cancer: open-label randomised phase 2 of datopotamab deruxtecan with durvalumab versus datopotamab deruxtecan alone, Barts London
- Sponsor: Queen Mary University of London, with AstraZeneca
- Enrolled: 140

## Notes

- UK sites (registry, 2): Barts Cancer Institute, Centre of Experimental Cancer Medicine, and Barts Health NHS Trust, London.

## Sources

- ClinicalTrials.gov NCT06954480: https://clinicaltrials.gov/study/NCT06954480
- ISRCTN registry search: datopotamab deruxtecan plus durvalumab (DIAMOND): https://www.isrctn.com/search?q=datopotamab+deruxtecan+durvalumab

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/), [TROP2](https://onco.cc/targets/trop2/)
- drugs: [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [Combined positive score (CPS)](https://onco.cc/terms/cps/), [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)
- trials: [A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer](https://onco.cc/trials/nct03742102/), [TROPION-Breast02](https://onco.cc/trials/tropion-breast02/), [TROPION-Breast05](https://onco.cc/trials/tropion-breast05/)

---
JSON: https://onco.cc/api/v1/entities/diamond.json